Androgen deprivation therapy promotes the expansion of cancer stem cells (CSCs) by altering the tumor microenvironment and upregulating key stem cell markers, including OCT4, SOX2, NANOG, CD133, and CD44, driving tumor initiation, progression, and recurrence in PCa [147,148]. The gene discussed is SOX2; the disease is posterior cortical atrophy.